Baxter International BAX Healthcare Systems & Technologies — Royalty rate
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Baxter International in its filing.
Tagged under the XBRL concept bax:ReportingUnitCashFlowPercentageRoyaltyRate.
The source filing: Baxter International’s 10-K, filed February 12, 2026.
- Filed
- Feb 12, 2026, 4:46 PM EST
- Fiscal year
- FY2025
- Accession
- 0001628280-26-007733
The fair value of the trade name intangible asset was determined using the relief from royalty method. Significant assumptions used in the determination of the fair value of the trade name intangible assets included revenue growth rates, a discount rate and a royalty rate. The relief from royalty model used in the determination of the fair value of our trade name intangible asset during 2025 reflected our most recent revenue projections, a discount rate of 9.0% and a royalty rate of 3.0%. Our trade name intangible asset fair value measurement is classified as Level 3 in the fair value hierarchy because it involves significant unobservable inputs.
Item 8. Financial Statements and Supplementary Data.
FAQ
- What is Baxter International's healthcare systems & technologies — royalty rate?
- Baxter International (BAX) reported healthcare systems & technologies — royalty rate of 3% in Q4 2025.
- What does healthcare systems & technologies — royalty rate mean?
- This metric represents the percentage of revenue paid to third parties for the use of licensed intellectual property, patents, or proprietary technologies integrated into the segment's product offerings. It is a key component of the cost structure for segments reliant on external innovation or collaborative R&D. High royalty rates can compress segment operating margins compared to peers who own their intellectual property outright.
Ask your AI about Baxter International's healthcare systems & technologies — royalty rate.
Connect your AI assistant and compare it to peers, right in your chat.
